Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy
Open Access
Abstract
Background: X-ALD is a white matter (WM) disease caused by mutations in the ABCD1 gene encoding the transporter of very-long-chain fatty acids (VLCFAs) into peroxisomes. Strikingly, the same ABCD1 mutation causes either devastating brain inflammatory demyelination during childhood or, more often, progressive spinal cord axonopathy starting in middle-aged adults. The accumulation of undegraded VLCFA in glial cell membranes and myelin has long been thought to be the central mechanism of X-ALD. Methods: This review discusses studies in mouse and drosophila models that have modified our views of X-ALD pathogenesis. Results: In the Abcd1 knockout (KO) mouse that mimics the spinal cord disease, the late manifestations of axonopathy are rapidly reversed by ABCD1 gene transfer into spinal cord oligodendrocytes (OLs). In a peroxin-5 KO mouse model, the selective impairment of peroxisomal biogenesis in OLs achieves an almost perfect phenocopy of cerebral ALD. A drosophila knockout model revealed that VLCFA accumulation in glial myelinating cells causes the production of a toxic lipid able to poison axons and activate inflammatory cells. Other mouse models showed the critical role of OLs in providing energy substrates to axons. In addition, studies on microglial changing substates have improved our understanding of neuroinflammation. Conclusions: Animal models supporting a primary role of OLs and axonal pathology and a secondary role of microglia allow us to revisit of X-ALD mechanisms. Beyond ABCD1 mutations, pathogenesis depends on unidentified contributors, such as genetic background, cell-specific epigenomics, potential environmental triggers, and stochasticity of crosstalk between multiple cell types among billions of glial cells and neurons.Keywords
Funding Information
- GETDOC (Groupe d’Etude et de Thérapeutique pour le Diabète, l’Obésité, la Croissance) Association (24/25-01)
This publication has 518 references indexed in Scilit:
- Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS‐275Annals of Clinical and Translational Neurology, 2020
- Symptoms in carriers of adrenoleukodystrophy relate to skewed X inactivationAnnals of Neurology, 2002
- Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screeningAnnals of Neurology, 2001
- Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophyAnnals of Neurology, 2001
- X-linked adrenoleukodystrophy enigma: How does the ALD peroxisomal transporter mutation affect CNS glia?Glia, 2000
- Targeted inactivation of the X-linked adrenoleukodystrophy gene in miceJournal of Neuroscience Research, 1997
- Progressive Spastic Paraparesis and Adrenal InsufficiencyArchives of Neurology, 1976
- AdrenoleukodystrophyArchives of Neurology, 1975
- AdrenoleukodystrophyArchives of Neurology, 1975
- Adreno-leukodystrophy (Sex-Linked Schilder Disease)Archives of Neurology, 1974